Stem Cell Clinic

MD Stem Cells Announces First Eye Patient Treated With Stem Cells in Florida Using New Technique

MD Stem Cells is pleased to announce the first treatment in the United States of a patient with eye disease using the new injection technique for stem cells they helped pioneer. Dr Steven Levy, President of MD Stem Cells, http://www.mdstemcells.com, indicated the procedure went very smoothly. The patient is anticipating a positive response within the next few months.

Fort Lauderdale, FL (PRWEB) November 14, 2012

"We have helped a number of eye patients utilize Bone Marrow Derived Stem Cells or BMSC for retinal and optic nerve diseases and have observed macular degeneration, myopic degeneration, hereditary retinopathies, optic nerve and glaucoma patients, among others, have visual improvements following treatment. Our retinal surgeon has used both subretinal surgery and different injection techniques in the past for the placement of BMSC in ocular disease. We collaboratively developed a dual injection technique that we believe takes advantage of the recently identified active vascular expulsion mechanism of cell transmigration and are very excited about our ability to deliver the BMSC to the RPE, retina and optic nerve. Dr Levy mentioned that the new technique has already been used by the retinal surgeon for a number of patients in Europe and after careful preparation is now being performed in the United States.

It was a worthwhile effort to arrange for the board certified physicians and operating rooms for the new procedure to be performed in the United States. We are extremely pleased to see this high level of adult stem cell treatment come to Florida.

The Europeans have had extensive experience using BMSC in a number of different diseases and believe their effectiveness to be significantly superior to adipose derived stem cells. It is their preferred source of adult stem cells. Certainly patients with ophthalmology disease have been treated with BMSC successfully.

The new dual injection approach appears to be resulting in a faster and more vigorous response for the eye patients exclaimed Dr Levy. The retinal surgeon has been surprised regarding the tissue regrowth and rapidity of visual improvement in several patients.

With respect to BMSC, better outcomes may depend on how well the health and viability of the stem cells is maintained as well as the quality of the surgery in placing the cells. With the MD Stem Cell providers, the autologous BMSC come directly from the patient themselves, undergo minimal manipulation during the isolation process and never leave the operating room so they can be reinjected almost immediately.

This delicate approach, coupled with the precise dual placement our experienced retinal surgeon provides, may be the explanation for the results we are seeing. Most ophthalmology patients will have a stem cell procedure only once and it makes sense to choose an approach that will give the best opportunity for improvement, opined Dr Levy.

Dr Levy indicated this particular patient suffered from optic nerve disease and that other scheduled patients will include AMD or macular degeneration, myopic degeneration and other diseases of the retina and optic nerve that can be expected to potentially benefit. We believe strongly that regenerative medicine is evolving and will expand in many directions over the next few years. We are excited to help bring access to this advanced stem cell technology to the USA for ophthalmology.

MD Stem Cells is a practice management and development organization working closely with adult stem cell providers globally. Inquires may be made directly to stevenlevy(at)mdstemcells(dot)com or visit our website http://www.mdstemcells.com.

View original post here:
MD Stem Cells Announces First Eye Patient Treated With Stem Cells in Florida Using New Technique

New Cell Type Developed For Possible Treatment Of Alzheimer's And Other Brain Diseases

UCI discovery accelerates efforts at Sue & Bill Gross Stem Cell Research Center

UC Irvine researchers have created a new stem cell-derived cell type with unique promise for treating neurodegenerative diseases such as Alzheimers.

Dr. Edwin Monuki of UCIs Sue & Bill Gross Stem Cell Research Center, developmental & cell biology graduate student Momoko Watanabe and colleagues developed these cells called choroid plexus epithelial cells from existing mouse and human embryonic stem cell lines.

CPECs are critical for proper functioning of the choroid plexus, the tissue in the brain that produces cerebrospinal fluid. Among their various roles, CPECs make CSF and remove metabolic waste and foreign substances from the fluid and brain.

In neurodegenerative diseases, the choroid plexus and CPECs age prematurely, resulting in reduced CSF formation and decreased ability to flush out such debris as the plaque-forming proteins that are a hallmark of Alzheimers. Transplant studies have provided proof of concept for CPEC-based therapies. However, such therapies have been hindered by the inability to expand or generate CPECs in culture.

Our method is promising, because for the first time we can use stem cells to create large amounts of these epithelial cells, which could be utilized in different ways to treat neurodegenerative diseases, said Monuki, an associate professor of pathology & laboratory medicine and developmental & cell biology at UCI.

The study appears in todays issue of The Journal of Neuroscience.

To create the new cells, Monuki and his colleagues coaxed embryonic stem cells to differentiate into immature neural stem cells. They then developed the immature cells into CPECs capable of being delivered to a patients choroid plexus.

These cells could be part of neurodegenerative disease treatments in at least three ways, Monuki said. First, theyre able to increase the production of CSF to help flush out plaque-causing proteins from brain tissue and limit disease progression. Second, CPEC superpumps could be designed to transport high levels of therapeutic compounds to the CSF, brain and spinal cord. Third, these cells can be used to screen and optimize drugs that improve choroid plexus function.

Monuki said the next steps are to develop an effective drug screening system and to conduct proof-of-concept studies to see how these CPECs affect the brain in mouse models of Huntingtons, Alzheimers and pediatric diseases.

Read the rest here:
New Cell Type Developed For Possible Treatment Of Alzheimer's And Other Brain Diseases

International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch

CARLSBAD, CA--(Marketwire - Nov 13, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced the commercial launch of its newest stem cell based skin care product by wholly-owned subsidiary Lifeline Skin Care, Inc.

The new Lifeline Eye Firming Complex is now available to shareholders, followers and supporters of ISCO and Lifeline Skin Care. The product will be available online (www.lifelineskincare.com), in selected spas and medical clinics on November 15, 2012.

Lifeline Eye Firming Complex complements the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices and online. The new, extended Lifeline product line will be promoted by recently engaged celebrities including Emme, the supermodel and author who was twice-named one of People magazine's 50 Most Beautiful People, and Glamour magazine's Woman of the Year; and Jennifer Galardi, a celebrity trainer, nationally recognized fitness and yoga guru, and the face for fitness brands Adidas, Under Armour, New Balance and Nike.

According to supermodel and beauty expert Emme, "Women are concerned about their appearance, and they're especially concerned about the lines and wrinkles around their eyes. That's why they'll like Lifeline's new eye cream -- women want something that really works."

Eye creams are considered a "must-have" in anti-aging skincare, and are typically the most popular product with customers. The new Eye Firming Complex includes novel ingredients designed to produce beneficial results, including peptides and HSC-X -- the human stem cell extract developed and patented by International Stem Cell Corporation which is used in the Company's anti-aging Day and Night serums.

"This addition to our skincare line has been highly anticipated," says Donna Queen, President of Lifeline Skin Care. "An eye treatment was the #1 request by our customers."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Go here to see the original:
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch

Lung Cancer Research Could Get Boost From New Stem Cell Findings

New research conducted at the University of Cincinnati (UC) Cancer Institute suggests that lung cancer stem cells can be successfully isolated and grown in a preclinical model. Such a process could provide a new method for investigating immunotherapy treatment options that target lung cancer stem cells.

Increasing evidence supports the idea that cancerous tumors have a population of stem cells, also called cancer-initiating cells, that continually regenerate and fuel cancer growth, explains Dr. John Morris, lead author of the study and professor at the UC College of Medicine. These cancer stem cells may also have the highest potential to spread to other organs.

The researchers stated that current research models provide limited information in the interaction between cancer stem cells and the immune system. They claim this makes it virtually impossible to study therapies that utilize the bodys immune system to fight off cancer.

The new study, published this week in PLOS One, successfully isolated lung cancer stem cells that can be used in a mouse model with full immune system function. The researchers used a tumorsphere assay test to accomplish this feat, allowing them to enrich their samples to isolate cancer stem cells.

The research team now hopes to develop more effective therapies that target cancer stem cells by showing how those cells escape the bodys immune system.

One of the hypotheses behind why cancer therapies fail is that the drug only kills cells deemed to be bad (because of certain molecular characteristics), but leaves behind stem cells to repopulate the tumor, said Morris. Stem cells are not frequently dividing, so they are much less sensitive to existing chemotherapies used to eliminate cells deemed abnormal.

Studying these unique cells could greatly improve our understanding of lung cancers origins and lead to the novel therapeutics targeting these cells and help to more effectively eradicate this disease. Immunotherapy is the future of cancer treatment. We are hopeful that this new method will accelerate our investigation of immunotherapies to specifically target cancer stem cells.

Read more:
Lung Cancer Research Could Get Boost From New Stem Cell Findings

Stem cell finding could advance immunotherapy for lung cancer

ScienceDaily (Nov. 13, 2012) A University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolated -- and then grown -- in a preclinical model, offering a new avenue for investigating immunotherapy treatment options that specifically target stem cells.

John C. Morris, MD, and his colleagues report their findings in the Nov. 13, 2012, issue of PLoS One, a peer-reviewed online publication.

Stem cells are unique cells that can divide and differentiate into specialized cells types -- for example cardiac muscle or liver tissue. These cells also have the ability to self-renew and produce more stem cells.

"Increasing evidence supports the idea that cancerous tumors have a population of stem cells, also called cancer-initiating cells, that continually regenerate and fuel cancer growth," explains Morris, senior author of the study and professor at the UC College of Medicine. "These cancer stem cells may also have the highest potential to spread to other organs."

Current models used to study cancer stem cells provide limited information on the interaction between cancer stem cells with the immune system, making the study of new therapies that utilize the body's immune system to fight off cancer virtually impossible.

In this study, the UC team set out to find a viable, consistent way to isolate lung cancer stem cells that could be used in a mouse model with full immune system function. The team was able to achieve this using a functional laboratory test known as "tumorsphere" assay.

The test -- which shows how cells grow in culture -- allowed them to enrich for cancer stem cells.

"Studying these unique cells could greatly improve our understanding of lung cancer's origins and lead to the novel therapeutics targeting these cells and help to more effectively eradicate this disease," adds Morris. "Immunotherapy is the future of cancer treatment. We are hopeful that this new method will accelerate our investigation of immunotherapies to specifically target cancer stem cells."

The team is working to characterize how cancer stem cells escape the body's immune system in order to develop more effective therapies that target stem cells.

"One of the hypotheses behind why cancer therapies fail is that the drug only kills cells deemed to be 'bad' (because of certain molecular characteristics), but leaves behind stem cells to repopulate the tumor," adds Morris. "Stem cells are not frequently dividing, so they are much less sensitive to existing chemotherapies used to eliminate cells deemed abnormal."

Read this article:
Stem cell finding could advance immunotherapy for lung cancer

Kyev/Kiev Sana Stem Cells Part 2…. – Video

Kyev/Kiev Sana Stem Cells Part 2....
Geoffrey in Kiev and stem cell treatment very calm as cutting G`s hair requires 3 people..From:ANGUS FILESViews:0 0ratingsTime:11:49More inNews Politics

Go here to see the original:
Kyev/Kiev Sana Stem Cells Part 2.... - Video

Hair Loss Treatment – Video

Hair Loss Treatment
At each cell division in your hair follicles on your scalp , the frequencies encoded in this video along with the subliminal and supraliminal progamming will cause those new cells to become or take on the attributes of embryonic stem cells, and also increase the concentration of human growth hormone, in your scalp all working towards stimulating and pushing for hair recovery, thickening and full growth. The end product should be you with a full head of hair. Effective and cost free. You can look at it as often as you wish for faster results. All sounds and images are the copyright of sapienmedicine.com (formerly projectvampire)From:projectvampireTVViews:1 2ratingsTime:10:02More inScience Technology

Original post:
Hair Loss Treatment - Video

DOH to issue guidelines on stem cell treatment in Philippines

By: Philippine News Agency November 11, 2012 8:29 AM

Stem cell tray. FILE PHOTO FROM AGENCE FRANCE-PRESSE/GETTY IMAGES

InterAksyon.com The online news portal of TV5

MANILA - The Department of Health (DOH) is expected to come up with the guidelines on the practice of stem cell treatment in the Philippines by the end of the month.

According to DOH Secretary Enrique Ona, the consultative working task force has already been convened to formulate recommendations on how to handle the growing popularity of stem cell technology among Filipinos.

Ona said that at present, stem cell therapy is still considered as an investigational intervention and there is still no scientific evidence about its efficacy, safety and quality.

Stem cell research employs both autologous (from same person) or allogenic (from another organism like animal or another human cell or tissue sample) method. Because there are many steps in the preparation of this lab and invasive procedure, there is therefore need to have a regulatory framework to protect Filipino citizens, he said.

Ona ordered the creation of the task force after observing the growing number of healthcare facilities that offer stem cell services. He was also concerned about the possible use of aborted fetuses or human embryos for the procedures.

The task force is composed of Food and Drug Administration acting director Dr. Kenneth Hartigan-Go, Philippine Council for Health Research and Development director Dr. Jaime Montoya, and scientists from the University of the Philippines National Institute of Health and Marine Science.

It will come up with regulatory framework covering five fundamental areas, namely: sources of raw stem cell materials; observance of good laboratory practices in the preparation of the tissue and the cells; credentialing of scientists involved in the technology; monitoring of marketing claims; and regulation or accreditation of facilities.

See the original post:
DOH to issue guidelines on stem cell treatment in Philippines

First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

The rest is here:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...